Stay updated on Nivolumab and SRS in Recurrent Meningioma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and SRS in Recurrent Meningioma Clinical Trial page.

Latest updates to the Nivolumab and SRS in Recurrent Meningioma Clinical Trial page
- Check6 days agoChange DetectedThe record’s latest submission and posting dates changed from July 2026 to November 2026, indicating a newer record update.SummaryDifference0.1%

- Check13 days agoChange DetectedThe page changes from a 403 error screen to the full ClinicalTrials.gov record for the nivolumab and stereotactic radiosurgery study, including its study details, eligibility criteria, locations, and consent forms.SummaryDifference98%

- Check20 days agoChange DetectedThe site revision identifier changed from v3.7.2 to v3.8.0 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check27 days agoChange DetectedA notice about NIH’s transition from “Artificial Intelligence” to “Super Intelligence” appears above the 403 error page.SummaryDifference1%

- Check34 days agoChange DetectedThe footer revision identifier changes from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check41 days agoChange DetectedThe site footer revision number changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

Stay in the know with updates to Nivolumab and SRS in Recurrent Meningioma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and SRS in Recurrent Meningioma Clinical Trial page.